JP2011516613A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011516613A5 JP2011516613A5 JP2011505164A JP2011505164A JP2011516613A5 JP 2011516613 A5 JP2011516613 A5 JP 2011516613A5 JP 2011505164 A JP2011505164 A JP 2011505164A JP 2011505164 A JP2011505164 A JP 2011505164A JP 2011516613 A5 JP2011516613 A5 JP 2011516613A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- posaconazole
- infection
- pharmaceutical composition
- acetate succinate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4517708P | 2008-04-15 | 2008-04-15 | |
| US61/045,177 | 2008-04-15 | ||
| PCT/US2009/040653 WO2009129301A2 (en) | 2008-04-15 | 2009-04-15 | Oral pharmaceutical compositions in a molecular solid dispersion |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011516613A JP2011516613A (ja) | 2011-05-26 |
| JP2011516613A5 true JP2011516613A5 (OSRAM) | 2013-03-21 |
Family
ID=41165581
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011505164A Withdrawn JP2011516613A (ja) | 2008-04-15 | 2009-04-15 | 好ましくはポサコナゾールおよびｈｐｍｃａｓを含む固体分散物中の経口用薬学的組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20110034478A1 (OSRAM) |
| EP (1) | EP2278957A2 (OSRAM) |
| JP (1) | JP2011516613A (OSRAM) |
| AU (1) | AU2009236290A1 (OSRAM) |
| CA (1) | CA2720851A1 (OSRAM) |
| WO (1) | WO2009129301A2 (OSRAM) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009129300A2 (en) * | 2008-04-15 | 2009-10-22 | Schering Corporation | High density compositions containing posaconazole and formulations comprising the same |
| US7635773B2 (en) | 2008-04-28 | 2009-12-22 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions |
| TW201010708A (en) * | 2008-06-02 | 2010-03-16 | Intervet Int Bv | Composition comprising an antibiotic and a corticosteroid |
| CA2840215A1 (en) * | 2011-06-22 | 2012-12-27 | Abhijit S. BAPAT | Conjugate-based antifungal and antibacterial prodrugs |
| ES2774901T3 (es) | 2012-02-15 | 2020-07-23 | Cydex Pharmaceuticals Inc | Proceso para la fabricación de derivados de ciclodextrina |
| RU2615385C2 (ru) | 2012-02-28 | 2017-04-04 | Сидекс Фармасьютикалс, Инк. | Композиции алкилированного циклодекстрина и способы их получения и применения |
| AU2013334921B2 (en) | 2012-10-22 | 2018-03-29 | Cydex Pharmaceuticals, Inc. | Alkylated cyclodextrin compositions and processes for preparing and using the same |
| PT3006049T (pt) | 2013-06-03 | 2018-03-20 | Shinetsu Chemical Co | Composição para extrusão por fusão a quente e método para produzir um produto extrudido por fusão a quente |
| EP2837391B1 (en) | 2013-08-12 | 2017-05-10 | Shin-Etsu Chemical Co., Ltd. | Hypromellose acetate succinate for use as hot-melt extrusion carrier, hot-melt extrusion composition, and method for producing hot-melt extrudate |
| US10851184B2 (en) | 2014-08-22 | 2020-12-01 | Cydex Pharmaceuticals, Inc. | Fractionated alkylated cyclodextrin compositions and processes for preparing and using the same |
| JP6203702B2 (ja) | 2014-11-18 | 2017-09-27 | 信越化学工業株式会社 | ヒプロメロース酢酸エステルコハク酸エステルを用いたスプレードライ用溶液及び固体分散体の製造方法 |
| MX2017006447A (es) | 2014-11-21 | 2018-01-30 | F2G Ltd | Agentes antifungicos. |
| EP3590505B1 (en) * | 2015-08-08 | 2024-11-06 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Gastro-resistant formulation containing posaconazole |
| EP3210599B1 (en) | 2016-02-26 | 2024-08-28 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Gastro-resistant formulation containing posaconazole and a polymeric precipitation inhibitor |
| WO2017032908A1 (en) * | 2016-07-08 | 2017-03-02 | Synthon B.V. | Pharmaceutical composition comprising amorphous posaconazole |
| CN106265526A (zh) * | 2016-09-22 | 2017-01-04 | 山东大学 | 一种抗真菌药物泊沙康唑的固体分散体及制备方法与应用 |
| US10702520B1 (en) | 2019-01-29 | 2020-07-07 | Slayback Pharma Llc | Pharmaceutical compositions of posaconazole |
| US11819503B2 (en) | 2019-04-23 | 2023-11-21 | F2G Ltd | Method of treating coccidioides infection |
| EP4196096A1 (en) | 2020-08-13 | 2023-06-21 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Gastro-resistant high-strength formulation containing posaconazole |
| EP4119128A1 (en) * | 2021-07-13 | 2023-01-18 | Dr. Falk Pharma Gmbh | Pharmaceutical composition for the oral administration of poorly soluble drugs comprising an amorphous solid dispersion |
| EP4091604B1 (en) | 2021-11-25 | 2024-04-03 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Granules containing posaconazole |
| AU2022324717A1 (en) | 2021-11-25 | 2024-06-13 | Alfred E. Tiefenbacher (Gmbh Und Co. Kg) | Granules containing posaconazole |
| WO2024041662A1 (zh) * | 2023-09-18 | 2024-02-29 | 北京德立福瑞医药科技有限公司 | 泊沙康唑固体分散体及其制备方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4144346A (en) * | 1977-01-31 | 1979-03-13 | Janssen Pharmaceutica N.V. | Novel 1-(1,3-dioxolan-2-ylmethyl)-1H-imidazoles |
| SE7804231L (sv) * | 1978-04-14 | 1979-10-15 | Haessle Ab | Magsyrasekretionsmedel |
| US4978672A (en) * | 1986-03-07 | 1990-12-18 | Ciba-Geigy Corporation | Alpha-heterocyclc substituted tolunitriles |
| US4916134A (en) * | 1987-03-25 | 1990-04-10 | Janssen Pharmacuetica N.V. | 4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]me]phenyl]-1-piperazinyl]phenyl]triazolones |
| US5278175A (en) * | 1990-02-02 | 1994-01-11 | Pfizer Inc. | Triazole antifungal agents |
| US5661151A (en) * | 1993-12-21 | 1997-08-26 | Schering Corporation | Tetrahydrofuran antifungals |
| US5703079A (en) * | 1993-12-21 | 1997-12-30 | Schering Corporation | Tetrahydrofuran antifungals |
| NZ270418A (en) * | 1994-02-07 | 1997-09-22 | Eisai Co Ltd | Polycyclic triazole & imidazole derivatives, antifungal compositions |
| US5790957A (en) * | 1995-09-12 | 1998-08-04 | Nokia Mobile Phones Ltd. | Speech recall in cellular telephone |
| US5834472A (en) * | 1996-05-24 | 1998-11-10 | Schering Corporation | Antifungal composition with enhanced bioavailability |
| US5846971A (en) * | 1996-06-28 | 1998-12-08 | Schering Corporation | Oral antifungal composition |
| US5972381A (en) * | 1996-06-28 | 1999-10-26 | Schering Corporation | Solid solution of an antifungal agent with enhanced bioavailability |
| US6713481B1 (en) * | 1997-10-17 | 2004-03-30 | David R. Andrews | Crystalline antifungal polymorph |
| BR9909666A (pt) * | 1998-03-26 | 2001-09-11 | Japan Tobacco Inc | Derivados de amida e antagonistas de nociceptina |
| AU2331801A (en) * | 1999-12-23 | 2001-07-09 | F.H. Faulding & Co. Limited | Improved pharmaceutical compositions for poorly soluble drugs |
| AR028253A1 (es) * | 2000-03-16 | 2003-04-30 | Pfizer Prod Inc | Inhibidores de la glucogeno fosforilasa |
| GB0104752D0 (en) * | 2001-02-27 | 2001-04-18 | Astrazeneca Ab | Pharmaceutical compositions |
| MXPA03009021A (es) * | 2001-04-03 | 2004-02-12 | Schering Corp | Composicion antifungal con biodisponibilidad aumentada. |
| US20060160823A1 (en) * | 2004-05-28 | 2006-07-20 | Leonore Witchey-Lakshmanan | Particulate-stabilized injectable pharmaceutical compositions of Posaconazole |
| US20060062848A1 (en) * | 2004-09-17 | 2006-03-23 | Nektar Therapeutics Uk Limited | Formulation comprising itraconazole |
| US20060275230A1 (en) * | 2004-12-10 | 2006-12-07 | Frank Kochinke | Compositions and methods for treating conditions of the nail unit |
| WO2007056205A2 (en) * | 2005-11-04 | 2007-05-18 | Eastman Chemical Company | Carboxyalkylcellulose esters for administration of poorly soluble pharmaceutically active agents |
| WO2009129300A2 (en) * | 2008-04-15 | 2009-10-22 | Schering Corporation | High density compositions containing posaconazole and formulations comprising the same |
-
2009
- 2009-04-15 AU AU2009236290A patent/AU2009236290A1/en not_active Abandoned
- 2009-04-15 US US12/937,881 patent/US20110034478A1/en not_active Abandoned
- 2009-04-15 CA CA2720851A patent/CA2720851A1/en not_active Abandoned
- 2009-04-15 EP EP09732492A patent/EP2278957A2/en not_active Withdrawn
- 2009-04-15 WO PCT/US2009/040653 patent/WO2009129301A2/en not_active Ceased
- 2009-04-15 JP JP2011505164A patent/JP2011516613A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011516613A5 (OSRAM) | ||
| de Lacerda Coriolano et al. | Antibacterial and antibiofilm potential of silver nanoparticles against antibiotic-sensitive and multidrug-resistant Pseudomonas aeruginosa strains | |
| Huang et al. | Self-assemblies based on traditional medicine berberine and cinnamic acid for adhesion-induced inhibition multidrug-resistant Staphylococcus aureus | |
| Pi et al. | Macrophage‐targeted isoniazid–selenium nanoparticles promote antimicrobial immunity and synergize bactericidal destruction of tuberculosis bacilli | |
| Macedo et al. | Usnic acid: From an ancient lichen derivative to promising biological and nanotechnology applications | |
| Ansari et al. | Recent advances in the therapeutic applications of selenium nanoparticles | |
| Das et al. | Silymarin nanoparticle prevents paracetamol-induced hepatotoxicity | |
| Ng et al. | In vitro evaluation of curcumin‐encapsulated chitosan nanoparticles against feline infectious peritonitis virus and pharmacokinetics study in cats | |
| Michaelis et al. | Effects of flavonoid-induced oxidative stress on anti-H5N1 influenza a virus activity exerted by baicalein and biochanin A | |
| CL2009000902A1 (es) | Composicion que comprende posaconazol disuelto o disperso molecularmente en un polimero derivado de hidroxipropilcelulosa; formulacion farmaceutica que comprende a la composion; un proceso para preparar a la composicion mediante fusioextrusion; y su uso para tratar una infeccion micotica. | |
| Lou et al. | Oridonin nanosuspension enhances anti-tumor efficacy in SMMC-7721 cells and H22 tumor bearing mice | |
| Do et al. | Advances in silver nanoparticles: unraveling biological activities, mechanisms of action, and toxicity | |
| Suresh et al. | Therapeutic potential of curcumin in ARDS and COVID‐19 | |
| BR112012030641A2 (pt) | métodos e composições para terapia farmacêutica oral | |
| Shin et al. | Comparison of anti-influenza virus activity and pharmacokinetics of oseltamivir free base and oseltamivir phosphate | |
| Yoosefian et al. | Silver nanoparticle-based drug delivery systems in the fight against COVID-19: enhancing efficacy, reducing toxicity and improving drug bioavailability | |
| Wollina | Peat: a natural source for dermatocosmetics and dermatotherapeutics | |
| Rai et al. | Harnessing bioactive nanocurcumin and curcumin nanocomposites to combat microbial pathogens: a comprehensive review | |
| Zeng et al. | Natural products and nanotechnology against coronavirus disease 2019 | |
| Ding et al. | Inhibitory effects of berberine on fungal growth, biofilm formation, virulence, and drug resistance as an antifungal drug and adjuvant with prospects for future applications | |
| Tavakoli et al. | Nanostructures for the Prevention, Diagnosis, and Treatment of COVID‐19: A Review | |
| Sotoudeheian et al. | Targeting SIRT1 by Scopoletin to Inhibit XBB. 1.5 COVID-19 Life Cycle | |
| A Marathe et al. | Herbal cocktail as anti-infective: promising therapeutic for the treatment of viral diseases | |
| Patel et al. | Potential of Nanotechnology-based Formulations in Combating Pulmonary Infectious Diseases: A Current Scenario | |
| WO2014197510A1 (en) | Composition prepared from saikosaponin, the use and the preparation method thereof |